Clinical Trials Logo

Advanced Malignant Solid Tumor clinical trials

View clinical trials related to Advanced Malignant Solid Tumor.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05098405 Terminated - Clinical trials for Advanced Malignant Solid Tumor

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Start date: October 11, 2021
Phase: Phase 1
Study type: Interventional

This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40. Preclinical studies suggest that MP0317 may provide benefit for the treatment of tumors known to express high levels of FAP and for which approved therapies have been exhausted. This is the first study of MP0317 in humans and its main purpose is to test its safety and tolerability in patients with advanced solid tumors. This study will also examine the blood levels of MP0317 at several increasing dose levels and a recommended dose for further development will be determined. The recommended dose will be tested in a second part of the study to confirm safety and to further assess the preliminary biologic and anti-tumor activity.